Preoperative transarterial chemoembolization (TACE) + liver resection versus upfront liver resection for large hepatocellular carcinoma (≥5 cm): a systematic review and meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. doi: 10.1016/S0140-6736(11)61347-0.
   PubMed Web of Science ®Google Scholar
• Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–1700.e3. doi: 10.1053/j.gastro.2014.02.032.
   PubMed Web of Science ®Google Scholar
• Chen H, Tao M, Li D, et al. An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist. Ann Transl Med. 2021;9(12):1004–1004. doi: 10.21037/atm-21-2611.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi: 10.1016/j.jhep.2021.11.018.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi: 10.1002/hep.29913.
   PubMed Web of Science ®Google Scholar
• Liang B-y, Gu J, Xiong M, et al. Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy. Sci Rep. 2021;11(1):16343. doi: 10.1038/s41598-021-95835-5.
   PubMed Web of Science ®Google Scholar
• Hong SK, Lee KW, Hong SY, et al. Efficacy of liver resection for single large hepatocellular carcinoma in Child-Pugh a cirrhosis: analysis of a nationwide cancer registry database. Front Oncol. 2021;11:674603. doi: 10.3389/fonc.2021.674603.
   PubMed Web of Science ®Google Scholar
• Hwang S, Lee YJ, Kim KH, et al. Long-Term outcome after resection of huge hepatocellular carcinoma ≥ 10 cm: single-Institution experience with 471 patients. World J Surg. 2015;39(10):2519–2528. doi: 10.1007/s00268-015-3129-y.
   PubMed Web of Science ®Google Scholar
• Zhou Y-M, Li B, Xu D-H, et al. Safety and efficacy of partial hepatectomy for huge (≥10 cm) hepatocellular carcinoma: a systematic review. Med Sci Monit. 2011;17(3):RA76–RA83. doi: 10.12659/msm.881443.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer. 1994;73(9):2259–2267. doi: 10.1002/1097-0142(19940501)73:9<2259::AID-CNCR2820730905>3.0.CO;2-P.
   PubMed Web of Science ®Google Scholar
• Si T, Chen Y, Ma D, et al. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in asia area: a meta-analysis of random controlled trials. Scand J Gastroenterol. 2016;51(12):1512–1519. doi: 10.1080/00365521.2016.1216588.
   PubMed Web of Science ®Google Scholar
• Li C, Wang MD, Lu L, et al. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis. Hepatol Int. 2019;13(6):736–747. doi: 10.1007/s12072-019-09981-0.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. doi: 10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
   Google Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. doi: 10.1186/1471-2288-14-135.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815–2834. doi: 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16. doi: 10.1186/1745-6215-8-16.
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg. 1995 1995;82(1):122–126. doi: 10.1002/bjs.1800820141.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang X, Wu L, et al. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. BMC Gastroenterol. 2013;13(1):51. doi: 10.1186/1471-230X-13-51.
   PubMedGoogle Scholar
• Mi S, Nie Y, Xie C. Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Scand J Gastroenterol. 2022;57(9):1070–1079. doi: 10.1080/00365521.2022.2057198.
   PubMed Web of Science ®Google Scholar
• Chen XP, Hu DY, Zhang ZW, et al. Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma. Dig Surg. 2007 2007;24(3):208–213. doi: 10.1159/000102901.
   PubMed Web of Science ®Google Scholar
• Choi GH, Kim DH, Kang CM, et al. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? World J Surg. 2007;31(12):2370–2377. Decdoi: 10.1007/s00268-007-9245-6.
   PubMed Web of Science ®Google Scholar
• El-Gendi AM, El-Shafei M, Bedewy E. Combined liver resection and transarterial chemoembolization versus liver resection alone for the management of solitary large exophytic hepatocellular carcinoma with extrahepatic arterial supply: is two always better than one? Egypt J Surg. 2018;37(1):78–88. doi: 10.4103/ejs.ejs_113_17.
   Web of Science ®Google Scholar
• Lu CD, Peng SY, Jiang XC, et al. Preoperative transcatheter arterial chemoembolization and prognosis of patients with hepatocellular carcinomas: retrospective analysis of 120 cases. World J Surg. 1999;23(3):293–300. doi: 10.1007/pl00013185.
   PubMed Web of Science ®Google Scholar
• Murakami M, Nagano H, Kobayashi S, et al. Effects of pre-operative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: implication of circulating cancer cells by detection of α-fetoprotein mRNA. Exp Ther Med. 2010;1(3):485–491. doi: 10.3892/etm_00000076.
   PubMed Web of Science ®Google Scholar
• Paye F, Jagot P, Vilgrain V, et al. Preoperative chemoembolization of hepatocellular carcinoma: a comparative study. Arch Surg. 1998;133(7):767–772. doi: 10.1001/archsurg.133.7.767.
   PubMedGoogle Scholar
• Wang JC, Hou JY, Chen JC, et al. Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. Eur J Cancer. 2021;155:85–96. doi: 10.1016/j.ejca.2021.07.009.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Takeishi K, Tsuijita E, et al. Beneficial effects of preoperative lipiodolization for resectable large hepatocellular carcinoma (≥ 5 cm in diameter). J Surg Oncol. 2012;106(4):498–503. doi: 10.1002/jso.23098.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xia F, Mo A, et al. Guiding value of circulating tumor cells for preoperative transcatheter arterial embolization in solitary large hepatocellular carcinoma: a single-center retrospective clinical study. Front Oncol. 2022;12:839597. doi: 10.3389/fonc.2022.839597.
   PubMed Web of Science ®Google Scholar
• Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009;249(2):195–202. doi: 10.1097/SLA.0b013e3181961c16.
   PubMed Web of Science ®Google Scholar
• Braunwarth E, Stättner S, Fodor M, et al. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg. 2018;50(3):100–112. doi: 10.1007/s10353-018-0537-x.
   PubMedGoogle Scholar
• Pollock R, Curley S, Ross M, Perrier N. Advanced therapy in surgical oncology. PMPH-USA: B.C. Decker Inc; 2008.
   Google Scholar
• Hyun MH, Lee YS, Kim JH, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology. 2018;68(3):977–993. doi: 10.1002/hep.29883.
   PubMed Web of Science ®Google Scholar
• Dai CY, Lin CY, Tsai PC, et al. Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. J Chin Med Assoc. 2018;81(2):155–163. doi: 10.1016/j.jcma.2017.06.018.
   PubMed Web of Science ®Google Scholar
• Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997;226(6):688–703. Decdiscussion 701-3. doi: 10.1097/00000658-199712000-00006.
   PubMed Web of Science ®Google Scholar
• Selby LKE, Tay RX, Woon WW, et al. Validity of the barcelona clinic liver cancer and Hong Kong liver cancer staging systems for hepatocellular carcinoma in Singapore. J Hepatobiliary Pancreat Sci. 2017;24(3):143–152. doi: 10.1002/jhbp.423.
   PubMed Web of Science ®Google Scholar
• Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–359. doi: 10.1055/s-0032-1329906.
   PubMed Web of Science ®Google Scholar
• Bai DS, Zhang C, Chen P, et al. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. doi: 10.1038/s41598-017-12834-1.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis GV, Vangeli M, et al. Systematic review: the model for end-stage liver disease–should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11–12):1079–1089. doi: 10.1111/j.1365-2036.2005.02691.x.
   PubMed Web of Science ®Google Scholar
• Labgaa I, Tabrizian P, Titano J, et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with yttrium-90 for unresectable hepatocellular carcinoma. HPB (Oxford). 2019;21(11):1497–1504. doi: 10.1016/j.hpb.2019.03.360.
   PubMed Web of Science ®Google Scholar
• Bouattour M, Fartoux L, Rosmorduc O, et al. BIOSHARE multicenter neoadjuvant phase 2 study: results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—from GERCOR IRC. J Clin Oncol. 2016;34(4_suppl):252–252. doi: 10.1200/jco.2016.34.4_suppl.252.
   Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi: 10.1056/NEJMoa1915745.
   PubMed Web of Science ®Google Scholar
• Moreno-Luna LE, Yang JD, Sanchez W, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36(3):714–723. doi: 10.1007/s00270-012-0481-2.
   PubMed Web of Science ®Google Scholar
• Ahmed S, De Souza NN, Qiao W, et al. Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg. 2016;2016:6120143–6120149. doi: 10.1155/2016/6120143.
   PubMedGoogle Scholar
• Nagasue N, Galizia G, Kohno H, et al. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery. 1989;106(1):81–86.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Tuo F, Li R, et al. Transarterial chemoembolization combined with hepatectomy for the treatment of intermediate-stage hepatocellular carcinoma. Front Oncol. 2020;10:578763. doi: 10.3389/fonc.2020.578763.
   PubMed Web of Science ®Google Scholar
• Leppink J, Winston K, O'Sullivan P. Statistical significance does not imply a real effect. Perspect Med Educ. 2016;5(2):122–124. doi: 10.1007/s40037-016-0256-6.
   PubMed Web of Science ®Google Scholar
• Uchida M, Kohno H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg. 1996;20(3):326–331. doi: 10.1007/s002689900052.
   PubMed Web of Science ®Google Scholar
• Ben-Ari Z, Hochhauser E, Burstein I, et al. Role of anti-tumor necrosis factor-alpha in ischemia/reperfusion injury in isolated rat liver in a blood-free environment. Transplantation. 2002;73(12):1875–1880. doi: 10.1097/00007890-200206270-00004.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Sugawara Y, Ohkubo T, et al. Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002;37(1):31–38. doi: 10.1016/s0168-8278(02)00084-3.
   PubMed Web of Science ®Google Scholar
• Won JY, Lee DY, Lee JT, et al. Supplemental transcatheter arterial chemoembolization through a collateral omental artery: treatment for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2003;26(2):136–140. doi: 10.1007/s00270-002-2629-y.
   PubMed Web of Science ®Google Scholar
• Li Z, Hu DY, Chu Q, et al. Cell apoptosis and regeneration of hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol. 2004;10(13):1876–1880. doi: 10.3748/wjg.v10.i13.1876.
   PubMed Web of Science ®Google Scholar
• Miksad RA, Ogasawara S, Xia F, et al. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer. 2019;19(1):795. Aug 13doi: 10.1186/s12885-019-5989-2.
   PubMed Web of Science ®Google Scholar
• Hai HH, Aw P, Teng TZJ, et al. Perioperative steroid administration reduces overall complications in patients undergoing liver resection: a meta-analysis. World J Gastrointest Surg. 2021;13(9):1079–1094. doi: 10.4240/wjgs.v13.i9.1079.
   PubMed Web of Science ®Google Scholar
• Lei GY, Shen L, Junnarkar SP, et al. Predictors of 90-day mortality following hepatic resection for hepatocellular carcinoma. Visc Med. 2021;37(2):102–109. doi: 10.1159/000510811.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223–238. doi: 10.1016/j.cld.2015.01.001.
   PubMed Web of Science ®Google Scholar